Your browser doesn't support javascript.
loading
Influence of Nucleoshuttling of the ATM Protein in the Healthy Tissues Response to Radiation Therapy: Toward a Molecular Classification of Human Radiosensitivity.
Granzotto, Adeline; Benadjaoud, Mohamed Amine; Vogin, Guillaume; Devic, Clément; Ferlazzo, Mélanie L; Bodgi, Larry; Pereira, Sandrine; Sonzogni, Laurène; Forcheron, Fabien; Viau, Muriel; Etaix, Aurélie; Malek, Karim; Mengue-Bindjeme, Laurence; Escoffier, Clémence; Rouvet, Isabelle; Zabot, Marie-Thérèse; Joubert, Aurélie; Vincent, Anne; Dalla Venezia, Nicole; Bourguignon, Michel; Canat, Edme-Philippe; d'Hombres, Anne; Thébaud, Estelle; Orbach, Daniel; Stoppa-Lyonnet, Dominique; Radji, Abderraouf; Doré, Eric; Pointreau, Yoann; Bourgier, Céline; Leblond, Pierre; Defachelles, Anne-Sophie; Lervat, Cyril; Guey, Stéphanie; Feuvret, Loic; Gilsoul, Françoise; Berger, Claire; Moncharmont, Coralie; de Laroche, Guy; Moreau-Claeys, Marie-Virginie; Chavaudra, Nicole; Combemale, Patrick; Biston, Marie-Claude; Malet, Claude; Martel-Lafay, Isabelle; Laude, Cécile; Hau-Desbat, Ngoc-Hanh; Ziouéche, Amira; Tanguy, Ronan; Sunyach, Marie-Pierre; Racadot, Séverine.
Affiliation
  • Granzotto A; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France.
  • Benadjaoud MA; INSERM UMRS 1018, Institut Gustave-Roussy, Villejuif, France.
  • Vogin G; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France; Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France.
  • Devic C; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France.
  • Ferlazzo ML; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France.
  • Bodgi L; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France; Université Saint-Joseph, Beirut, Lebanon.
  • Pereira S; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France.
  • Sonzogni L; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France.
  • Forcheron F; Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France.
  • Viau M; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France.
  • Etaix A; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France.
  • Malek K; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France.
  • Mengue-Bindjeme L; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France.
  • Escoffier C; Centre de Biotechnologie Cellulaire et Biothèque, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.
  • Rouvet I; Centre de Biotechnologie Cellulaire et Biothèque, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.
  • Zabot MT; Centre de Biotechnologie Cellulaire et Biothèque, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.
  • Joubert A; Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, France.
  • Vincent A; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France.
  • Dalla Venezia N; INSERM, UMR1052, Cancer Research Centre of Lyon, Lyon, France.
  • Bourguignon M; Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, France.
  • Canat EP; Clinique Jean-Mermoz, Lyon, France.
  • d'Hombres A; Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Thébaud E; Centre Hospitalier Universitaire, Nantes, France.
  • Orbach D; Institut Curie, Paris, France.
  • Stoppa-Lyonnet D; Institut Curie, Paris, France.
  • Radji A; Centre Joliot-Curie, Rouen, France.
  • Doré E; Centre Hospitalier Universitaire, Clermont-Ferrand, France.
  • Pointreau Y; Centre Hospitalier Régional Universitaire Bretonneau, Tours, France.
  • Bourgier C; Institut du Val d'Aurelle, Montpellier, France.
  • Leblond P; Centre Oscar-Lambret, Lille, France.
  • Defachelles AS; Centre Oscar-Lambret, Lille, France.
  • Lervat C; Centre Oscar-Lambret, Lille, France.
  • Guey S; Hôpital La Pitié-Salpétrière, Assistance Publique des Hôpitaux de Paris, Paris, France.
  • Feuvret L; Hôpital La Pitié-Salpétrière, Assistance Publique des Hôpitaux de Paris, Paris, France.
  • Gilsoul F; Hôpital Saint Joseph, Charleroi, Belgique.
  • Berger C; Centre Hospitalier Universitaire, Saint-Etienne, France.
  • Moncharmont C; Centre Hospitalier Universitaire, Saint-Etienne, France.
  • de Laroche G; Centre Hospitalier Universitaire, Saint-Etienne, France.
  • Moreau-Claeys MV; Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France.
  • Chavaudra N; Institut Gustave-Roussy, Villejuif, France.
  • Combemale P; Centre Léon-Bérard, Lyon, France.
  • Biston MC; Centre Léon-Bérard, Lyon, France.
  • Malet C; Centre Léon-Bérard, Lyon, France.
  • Martel-Lafay I; Centre Léon-Bérard, Lyon, France.
  • Laude C; Centre Léon-Bérard, Lyon, France.
  • Hau-Desbat NH; Centre Léon-Bérard, Lyon, France; Centre Hospitalier Métropôle-Savoie, Chambéry, France.
  • Ziouéche A; Centre Léon-Bérard, Lyon, France.
  • Tanguy R; Centre Léon-Bérard, Lyon, France.
  • Sunyach MP; Centre Léon-Bérard, Lyon, France.
  • Racadot S; Centre Léon-Bérard, Lyon, France.
Int J Radiat Oncol Biol Phys ; 94(3): 450-60, 2016 Mar 01.
Article in En | MEDLINE | ID: mdl-26867874
ABSTRACT

PURPOSE:

Whereas post-radiation therapy overreactions (OR) represent a clinical and societal issue, there is still no consensual radiobiological endpoint to predict clinical radiosensitivity. Since 2003, skin biopsy specimens have been collected from patients treated by radiation therapy against different tumor localizations and showing a wide range of OR. Here, we aimed to establish quantitative links between radiobiological factors and OR severity grades that would be relevant to radioresistant and genetic hyperradiosensitive cases. METHODS AND MATERIALS Immunofluorescence experiments were performed on a collection of skin fibroblasts from 12 radioresistant, 5 hyperradiosensitive, and 100 OR patients irradiated at 2 Gy. The numbers of micronuclei, γH2AX, and pATM foci that reflect different steps of DNA double-strand breaks (DSB) recognition and repair were assessed from 10 minutes to 24 hours after irradiation and plotted against the severity grades established by the Common Terminology Criteria for Adverse Events and the Radiation Therapy Oncology Group.

RESULTS:

OR patients did not necessarily show a gross DSB repair defect but a systematic delay in the nucleoshuttling of the ATM protein required for complete DSB recognition. Among the radiobiological factors, the maximal number of pATM foci provided the best discrimination among OR patients and a significant correlation with each OR severity grade, independently of tumor localization and of the early or late nature of reactions.

CONCLUSIONS:

Our results are consistent with a general classification of human radiosensitivity based on 3 groups radioresistance (group I); moderate radiosensitivity caused by delay of nucleoshuttling of ATM, which includes OR patients (group II); and hyperradiosensitivity caused by a gross DSB repair defect, which includes fatal cases (group III).
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radiation Injuries / Radiation Tolerance / Skin / Histones / Cell Nucleus / DNA Breaks, Double-Stranded / Ataxia Telangiectasia Mutated Proteins Type of study: Prognostic_studies Limits: Humans Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2016 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radiation Injuries / Radiation Tolerance / Skin / Histones / Cell Nucleus / DNA Breaks, Double-Stranded / Ataxia Telangiectasia Mutated Proteins Type of study: Prognostic_studies Limits: Humans Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2016 Document type: Article Affiliation country: France
...